Neurocrine Biosciences | NBIX - Zahlungsmittel Und Äquivalente





Zahlungsmittel Und Äquivalente Veränderung Datum
AbbVie USD 6.57B 2.82B 2026-06
Acadia Pharmaceuticals USD 956.47M 105.02M 2026-06
Agios Pharmaceuticals USD 99.65M 13.95M 2026-06
ALKERMES USD 511.53M 159.98M 2026-06
Alnylam Pharmaceuticals USD 1.71B 2.46M 2026-06
Amgen USD 13.99B 1.95B 2026-06
Biogen USD 1.28B 2.1B 2026-06
BioMarin Pharmaceutical USD 874M 1.35B 2026-06
Cytokinetics USD 255.27M 125.43M 2026-06
Enanta Pharmaceuticals USD 37.44M 5.14M 2025-12
Exelixis USD 281.45M 55.3M 2026-06
Gilead Sciences USD 7.63B 64M 2026-03
Halozyme Therapeutics USD 163.14M 146.61M 2026-06
Incyte USD 3.98B 33.45M 2026-06
Ionis Pharmaceuticals USD 350.06M 1.57B 2026-06
Nektar Therapeutics USD 149.58M 134.46M 2026-03
Neurocrine Biosciences USD 332.4M 65.9M 2026-06
Pfizer USD 976M 727M 2026-06
Prothena USD 288.19M 41.27M 2026-06
Regeneron Pharmaceuticals USD 2.46B 506.8M 2026-06
Repligen USD 606.78M 24.13M 2026-06
Rigel Pharmaceuticals USD 48.53M 4.87M 2025-09
Sarepta Therapeutics USD 571.15M 106.7M 2026-06
Teva Pharmaceutical Industries USD 3.74B 185M 2026-03
Ultragenyx Pharmaceutical USD 125M 50M 2026-06
Vertex Pharmaceuticals USD 7.85B 605.7M 2026-06